[e-drug] A new ARV price report from WHO

["Tamura, Kenji" <tamurak@who.int>]

E-DRUG: A new ARV price report from WHO
---------------------------------------

Prices of ARVs continue to decline for the first-line regimen

The new summary report by the WHO/AMDS Global Price Reporting Mechanism
(GPRM) confirms that median prices of the most commonly prescribed ARVs
in fixed dose combination (stavudine 30 mg + lamivudine 150 mg +
nevirapine 200 mg) continued to decline during the period from January
to June 2007. They are now available for less than US$ 100 per patient
per year (pppy) with a median price of US$ 77 in low-income countries
and US$ 99 in middle-income countries.  

The same trend is being observed with ARVs for children. However, the
costs of oral solutions for infants/young children still remain high.
For instance, the median cost of the most widely prescribed regimen as
oral solution (zidovudine 10 mg/ml + lamivudine 10 mg/ml + nevirapine 10
mg/ml) for a five kg infant is now US$ 174 (pppy) in low-income
countries and US$ 235 (pppy) in middle-income countries.   

To read more about the price data analyzed for the second-line and other
regimens, click here (summary report July 2007)

http://www.who.int/hiv/amds/GPRMsummaryJuly2007.pdf

WHO/AMDS cordially invites readers of the summary report to send their
comments and suggestions to amds@who.int 

We would particularly welcome your ideas as to how the price and
procurement data of ARVs should be analyzed in the future report. 

kind regards

Kenji Tamura MD PhD 
Medical Officer 
AIDS Medicines and Diagnostics Service (AMDS)
System Strengthening and HIV                       
Department of HIV/AIDS 
20 Avenue Appia, CH-1211 
Geneva 27 Switzerland 
tamurak@who.int 
phone 22-791-1641 
fax      22-791-4887 
WHO/HTM/HIV/SSH/AMDS  
http://www.who.int//hiv/amds/en <http://www.who.int/hiv/amds/en>